Tradestie Institutional Equity Comparison Engine

DXCM vs PHG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DXCM Overall Edge

DXCM Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PHG counters with relative strength in Valuation. Fundamentally, DXCM trades at 25.3x Forward P/E with 24.0% operating margin (+11.2% YoY revenue) versus PHG at 14.0x Forward P/E and 8.8% operating margin (+2.1% YoY). In options structure, DXCM sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro) against PHG sits in SURGE (51st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PHG
DXCM 25.3x vs PHG 14.0x Fwd P/E
Growth & Margin Winner DXCM
Op Margin 24.0% vs 8.8% ยท YoY +11.2% vs +2.1%
Momentum & Technical Winner DXCM
1Y +32.8% vs +5.7% ยท 52W Pos 63% vs 51%
Options & Structure Winner DXCM
CONSOLIDATION (15th %ile IV) vs SURGE (51st %ile IV)
DXCM NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
1M Return +1.28%
1Y Return +32.8%
Forward P/E 25.3x
Unified AI Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
PHG NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap $28.6B
1M Return +6.28%
1Y Return +5.73%
Forward P/E 14.0x
Unified AI Score
40.3 / 100 SELL
Tech 15.0 Fund 39.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DXCM +32.8% PHG +5.73% Spread: +27.07 pp (DXCM Lead)

Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DXCM Revenue PHG Revenue DXCM Op. Margin PHG Op. Margin Margin Edge
Q3 '25 $4.84B $17.2B 20.1% 7.7% DXCM
Q4 '25 $5.04B $20.4B 25.6% 11.1% DXCM
Q1 '26 $4.77B $15.6B 21.4% 6.2% DXCM
Q2 '26 $5.23B $17.4B 24.3% 14.0% DXCM
Q3 '26 $5.38B $17.6B 24.3% 3.8% DXCM

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DXCM (7) vs PHG (3)
Institutional Metric DXCM PHG Criterion Row Winner
Market Capitalization Scale $29.9B $28.6B Larger Scale DXCM
Trailing P/E Ratio Valuation 31.6x 25.4x Lower Multiple PHG
Forward P/E Ratio Valuation 25.3x 14.0x Lower Multiple PHG
Revenue Growth (YoY) Growth +11.2% +2.1% Higher Growth DXCM
Operating Margin (TTM) Profitability 24.0% 8.8% Higher Margin DXCM
Net Profit Margin Profitability 19.4% 5.4% Higher Margin DXCM
Return on Equity (ROE) Capital Efficiency 37.7% 8.6% Higher ROE DXCM
52-Week Range Position Momentum 63% ($57โ€“$93) 51% ($24โ€“$33) Stronger Trend DXCM
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 43% Vol 0.71ฮฒ ยท 38% Vol Lower Realized Risk PHG
Unified Institutional Score Composite Signal 50.8 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite DXCM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DXCM vs PHG Buy Guide
DXCM CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 15th %ile
IV Regime Compressed (<25th %ile)
Live DXCM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PHG SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 51st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PHG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DXCM nor PHG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.